-
1.
MacDougall IC, et al.. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 2019; 380:447–458.
-
2.
Besarab A, et al.. The effects of normal versus anemic hematocrit on hemodialysis patients with cardiac disease. N Eng J Med 1998; 339:584–590.
-
3.
Singh AK, et al.. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085–2098.
-
4.
Pfeffer MA, et al.. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Eng J Med 2009; 361:2019–32.
-
5.
Feldman HI, et al.. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002; 13:734–44.
-
6.
Szczech LA, et al.. Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes. Kidney Int 2008; 74:791–798.
-
7.
McCullough P, et al.. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol 2013; 37:549–58.
-
8.
Solomon SD, et al.. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010; 363:1146–55.
-
9.
Macdougall IC, et al.. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenouslv. BMJ 1989; 299:157–158.
-
10.
Anker S, et al.. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361:2436–2448.
Trials and Tribulations: NHT, CHOIR, TREAT, PIVOTAL
The balance between iron and ESA dose
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory